| 6.98 0.04 (0.58%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.52  |
1-year : | 9.95 |
| Resists | First : | 7.3 |
Second : | 8.52 |
| Pivot price | 6.45 |
|||
| Supports | First : | 5.35 |
Second : | 4.15 |
| MAs | MA(5) : | 6.65 |
MA(20) : | 6.05 |
| MA(100) : | 5.06 |
MA(250) : | 4.04 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 91.2 |
D(3) : | 90.2 |
| RSI | RSI(14): 72 |
|||
| 52-week | High : | 7.3 | Low : | 1.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TSHA ] has closed above the upper band by 0.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.31 - 7.34 | 7.34 - 7.36 |
| Low: | 6.43 - 6.46 | 6.46 - 6.49 |
| Close: | 6.93 - 6.98 | 6.98 - 7.03 |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Wed, 06 May 2026
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Australia
Wed, 06 May 2026
Rising R&D spend widens Taysha Gene Therapies (NASDAQ: TSHA) Q1 loss - Stock Titan
Wed, 06 May 2026
Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway - Stock Titan
Wed, 06 May 2026
A 6-month trial readout could shape Taysha's gene therapy filing - Stock Titan
Wed, 06 May 2026
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Fri, 01 May 2026
Five new Taysha hires get 188,000 stock units under Nasdaq rule - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 287 (M) |
| Shares Float | 198 (M) |
| Held by Insiders | 10.6 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 38,920 (K) |
| Shares Short P.Month | 46,390 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 0 % |
| Operating Margin | -516 % |
| Return on Assets (ttm) | -27.5 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | 171.3 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -20.53 |
| PEG Ratio | 0 |
| Price to Book value | 8.02 |
| Price to Sales | 205.28 |
| Price to Cash Flow | -21.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|